Severe type 2 asthma remains difficult to manage when inhaled therapy fails, and the expanding biologic arsenal raises a practical question: which agent, for which patient, and how do we measure success outside a controlled trial? Three papers published in 2026 address that gap directly, drawing on real-world cohorts and comparative reviews to test whether trial-era promises hold in everyday practice.
- The Pivot Real-world evidence for dupilumab in severe type 2 asthma is now accumulating across European cohorts, moving the evidence base beyond phase III trial populations.
- The Data Structured effectiveness tools including FEOS and EXACTO are being applied to real-world dupilumab cohorts, though the evidence supporting their predictive validity remains limited.1
- The Action Prescribing clinicians should document outcomes systematically using available effectiveness frameworks, while recognising that head-to-head comparative data across biologics in this setting are still scarce.2
Dupilumab, the IL-4/IL-13 receptor antagonist from Sanofi and Regeneron, demonstrated efficacy in severe asthma across its phase III programme, but trial populations are selected, monitored, and rarely representative of the patients sitting in a respiratory clinic on a Tuesday afternoon. The three studies reviewed here attempt to close that distance.
Tools designed to evaluate biologic effectiveness in real-world asthma practice, specifically FEOS and EXACTO, have attracted interest as structured frameworks for assessing response. However, the evidence base supporting their clinical validity in routine use remains limited.1 That caveat matters: without validated outcome instruments, comparing effectiveness across centres or across agents becomes methodologically treacherous.
What the studies did
The DUPImpact study, a Spanish multicentre investigation, evaluated dupilumab in a cohort of patients with uncontrolled severe type 2 asthma in real-world clinical settings.1 The Romanian 24-month cohort study examined long-term clinical and biological outcomes of biologic therapy more broadly in severe asthma, tracking patients over two years to assess durability of response.2 A third paper from Lombardi and Menzella took a different approach, conducting a comparative review of biologic therapies with a focus on dual clinical remission in patients carrying both severe asthma and chronic rhinosinusitis with nasal polyps, a comorbidity profile that is common and therapeutically relevant.3
Across all three publications, the investigators acknowledge that real-world evidence for dupilumab in asthma remains limited relative to the volume of phase III data available.1,2,3 The Romanian cohort is notable for its 24-month follow-up window, which allows at least a preliminary view of whether early biologic responses are sustained.2 The comparative review by Lombardi and Menzella addresses a clinically important question: in patients with overlapping type 2 inflammatory disease affecting both the lower and upper airway, the choice of biologic carries implications for both conditions simultaneously.3 Dupilumab's approval across both indications gives it a structural advantage in that dual-disease population, though the review frames this in terms of achieving clinical remission across both sites rather than simply symptom reduction.3
The shared limitation across all three studies is the absence of hard comparative statistics in the abstracts available for review. Specific outcome figures, including exacerbation rates, lung function changes, and oral corticosteroid reduction data, are not reported in the source material provided. Readers requiring granular numbers should access the full publications directly. What the body of work does establish is a methodological conversation: how should clinicians define and measure success with biologics in asthma, and are current tools fit for that purpose?1,2,3
The most striking feature of this emerging evidence base is not what it shows, but what it still cannot show. Three independent research groups across Spain, Romania, and an international review consortium are all circling the same admission: real-world evidence for dupilumab in severe asthma is thin. That is not a criticism of the drug. It is a systems failure. Severe asthma biologics have been in clinical use long enough that structured outcome registries should by now be generating the kind of longitudinal data that makes prescribing decisions defensible. They are not, at least not consistently, and the reliance on tools like FEOS and EXACTO whose predictive validity remains unconfirmed compounds the problem.
The dual-disease angle examined by Lombardi and Menzella deserves more attention than it typically receives in respiratory clinics. A patient with severe asthma and chronic rhinosinusitis with nasal polyps is not two patients. They are one patient who may benefit from an agent that addresses both inflammatory pathways in a single prescription, and dupilumab's approval across both indications gives Sanofi and Regeneron a commercial and clinical argument that mepolizumab, benralizumab, and tezepelumab cannot straightforwardly match in this subgroup. Whether that translates into genuine dual remission in practice is precisely what comparative real-world data should be answering, and the literature is not yet there.
Patients in this setting carry a significant burden: frequent exacerbations, oral corticosteroid exposure, and in many cases undertreated upper airway disease running alongside their asthma. The 24-month Romanian cohort is a step toward understanding whether biologic benefits are durable rather than front-loaded, which matters enormously for treatment continuation decisions and for commissioning bodies evaluating cost-effectiveness. Until that data matures and outcome measurement frameworks are validated, clinicians are making well-informed but still partly empirical choices. Documenting those choices rigorously is not optional housekeeping. It is the only way the field generates the evidence it currently lacks.
ART-2026-002
How to cite this article
Lopes W. Dupilumab in severe asthma: real-world cohort data begin to arrive. The Life Science Feed. Updated May 6, 2026. Accessed May 6, 2026. https://thelifesciencefeed.com/pulmonology/asthma/research/dupilumab-in-severe-asthma-real-world-cohort-data-begin-to-arrive.
Copyright and license
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Fact-Checking & AI Transparency
This article was researched and drafted with AI assistance, then reviewed and approved for publication by the Editor. All content is sourced from peer-reviewed, open-access research. It does not represent the views of any pharmaceutical company or healthcare provider.
Our AI tools are used to summarise and structure published research only. Every article is checked by a human editor before going live — no article is published without editorial review.
References
1. Izaguirre-Flores H, Arismendi E, Martin-Ruiz de la Rosa E. Real-world experience with dupilumab in severe asthma: the Spanish multicenter study DUPImpact. J Investig Allergol Clin Immunol. 2026. PMID:41906934
2. Marginean C, Safta AC, Hutanu D. Long-term clinical and biological outcomes of biologic therapy in severe asthma: 24-month real-world cohort study from Romania. J Clin Med. 2026. PMID:41899366
3. Lombardi C, Menzella F. Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies. Expert Opin Biol Ther. 2026. PMID:41873839
Stay ahead in Life Science
Evidence-based clinical updates, trial results, and practice-changing research — delivered to your inbox.